You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

Investigational Drug Information for Guadecitabine


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Guadecitabine?

Guadecitabine is an investigational drug.

There have been 28 clinical trials for Guadecitabine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Preleukemia. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are four US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for Guadecitabine
TitleSponsorPhase
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic SyndroM.D. Anderson Cancer CenterPhase 2
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Astex Pharmaceuticals, Inc.Phase 2

See all Guadecitabine clinical trials

Clinical Trial Summary for Guadecitabine

Top disease conditions for Guadecitabine
Top clinical trial sponsors for Guadecitabine

See all Guadecitabine clinical trials

US Patents for Guadecitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Guadecitabine ⤷  Sign Up Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
Guadecitabine ⤷  Sign Up Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
Guadecitabine ⤷  Sign Up Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acr- ylamide and uses thereof MEI PHARMA, INC. (San Diego, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.